Poster-Disease-modifying Therapy

Poster-Disease-modifying Therapy

Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and...

Read More

Poster-Disease-modifying Therapy

Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders

Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Poster-Disease-modifying Therapy

Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study

Background: In relapsing forms of Multiple Sclerosis, disability progression has been shown to be independent of relapses. A new concept in...

Read More

Poster-Disease-modifying Therapy

Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)

Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....

Read More

Poster-Disease-modifying Therapy

MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity

Background: NEDA or No evidence of disease activity (relapses, MRI lesions and disease progression) is increasingly used as a meaningful...

Read More

Poster-Disease-modifying Therapy

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More